STARPHARMA HOLDINGS LTD

Starpharma Holdings sees a 42% decline amid breakthrough Phase 1 plans for its HER2‑Lu drug and a new partnership with Genentech, bolstering its oncology pipeline.

Starpharma shares fall 4% to AUD 0.47, its steepest one‑day drop since listing, amid broader commodity‑sector sell‑off; explore the biopharma’s oncology pipeline.

Starpharma shares tumble 33% amid new majority stake in Petalion, fueling a bold oncology strategy shift and fresh R&D focus.